➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Moodys
Merck
Harvard Business School
Johnson and Johnson
AstraZeneca

Last Updated: December 2, 2020

DrugPatentWatch Database Preview

Details for Patent: 9,173,851

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,173,851 protect, and when does it expire?

Patent 9,173,851 protects PROCYSBI and is included in two NDAs.

Protection for PROCYSBI has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has twenty-seven patent family members in twenty-two countries.

Summary for Patent: 9,173,851
Title:Delayed release cysteamine bead formulation, and methods of making and using same
Abstract: An enteric-coated bead dosage form of cysteamine, and related methods of manufacture and use, are disclosed.
Inventor(s): Powell; Kathlene (Cary, NC), Muttavarapu; Ramesh (Durham, NC)
Assignee: RAPTOR PHARMACEUTICALS INC. (Novato, CA)
Application Number:14/751,639
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,173,851
Patent Claim Types:
see list of patent claims
Composition; Dosage form; Formulation;

Drugs Protected by US Patent 9,173,851

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Horizon Pharma Usa PROCYSBI cysteamine bitartrate GRANULE, DELAYED RELEASE;ORAL 213491-001 Feb 14, 2020 RX Yes No   Start Trial   Start Trial Y   Start Trial
Horizon Pharma Usa PROCYSBI cysteamine bitartrate GRANULE, DELAYED RELEASE;ORAL 213491-002 Feb 14, 2020 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Horizon Pharma Usa PROCYSBI cysteamine bitartrate CAPSULE, DELAYED RELEASE;ORAL 203389-001 Apr 30, 2013 RX Yes No   Start Trial   Start Trial Y   Start Trial
Horizon Pharma Usa PROCYSBI cysteamine bitartrate CAPSULE, DELAYED RELEASE;ORAL 203389-002 Apr 30, 2013 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,173,851

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 096628   Start Trial
Australia 2014281702   Start Trial
Brazil 112015031417   Start Trial
Canada 2914770   Start Trial
Canada 2938644   Start Trial
Chile 2015003662   Start Trial
China 105492000   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
McKinsey
Moodys
Colorcon
Merck
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.